Biophytis
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
-6.62
19
Biophytis SA operates as a clinical-stage biotechnology company. The company employs 18 full-time employees The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Biophytis SA operates as a clinical-stage biotechnology company. The company employs 18 full-time employees The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.